We have started a new biotech company called Treeline Biosciences. The name is meant to connote the outer edge of scientific possibility, where conditions are challenging but the metaphorical trees still grow. The company will prioritize molecular targets in oncology that are validated but difficult to drug. If successful, we believe that our approaches could apply to other therapeutic areas as well.
